Christie Digital Christie Digital

Far-UVC light

Is 222nm the answer?

The technology we need right now

We need ongoing solutions to defend ourselves from pathogens to reduce their incredible impact on our families, businesses, schools, and communities.

We need safe and effective technology for indoor public spaces where people gather—from airports, schools, and public transportation to all forms of entertainment venues—that can effectively reduce pathogens.

222nm: A sweet spot on the UV spectrum

Promising new studies show that shorter UVC wavelengths—with the sweet spot being 222nm—have the unique ability to significantly reduce pathogens and may also be used around people.

Recent research shows that shorter wave, far-UVC 222nm light—paired with a short pass filter that prevents longer wavelengths from being emitted—can effectively reduce pathogens like the SARS-CoV-2 coronavirus that causes COVID-19 as well as harmful bacteria, influenza, and antibiotic-resistant superbugs like MRSA, and may also be used around people.


Read the far-UVC 222nm white paper

Read the Far-UVC 222NM white paper

What’s the difference between 254nm and 222nm far-UVC light?

This graphic clearly illustrates how 254nm (and longer) wavelengths are able to damage our eyes—including incurable diseases like macular degeneration—because wavelengths of 230nm and above can penetrate our eyes.

This graphic illustrates a significant difference between 254nm and 222nm light: the shorter wavelengths of far-UVC 222nm light have a limited ability to penetrate past the outer layer of our skin. This layer, the stratum corneum, consists of dead skin cells and serves as the primary barrier between our bodies and the environment.

SARS-CoV-2 coronavirus. This graphic illustrates how far-UVC 222nm light penetrates and inactivates coronaviruses like SARS-CoV-2 (COVID-19) by damaging its RNA.

Now there’s a way to reduce pathogens like coronaviruses

Christie® CounterAct products with patented Care222® technology emit filtered far-UVC 222nm light that’s been shown in the lab to inactivate more than 99% of surface pathogens—including SARS-CoV-2 (COVID-19), influenza, bacteria, and antibiotic-resistant superbugs.

Care222 is the world’s first far-UVC technology that may be used around people and is effective in reducing pathogens, and the only that contains a proprietary filter to prevent longer UVC wavelengths from being emitted.


Visit the Christie CounterAct microsite »

Visit the Christie CounterAct microsite

Patented, proprietary Care222 far-UVC technology

Care222 excimer lamps produce far-UVC 222nm light

Here’s how: Care222 excimer lamps contain a chamber filled with noble gas that doesn’t use inner electrodes and is completely mercury-free. High voltage applied across the outside of the glass excites the gas inside, causing far-UVC 222nm light to be emitted. And the construction of Care222 lamps allow them to instantly turn on or off without warm-up time or decreased lifetime, unlike other similar lamps.

Read the Far-UVC 222NM white paper

The only 222nm lamps with a proprietary narrowband filter

Care222’s proprietary short pass filter prevents wavelengths of UV light (230nm and higher) that present a human health hazard from being emitted—an especially important feature that other 222nm and far-UVC-emitting products do not have.


Visit the Christie CounterAct microsite »

Read the Far-UVC 222NM white paper

Technology backed by research: What the studies say

Columbia University Irving Medical Center – February 2017

A Columbia University Irving Medical Center study published in February 2017 found that far-UVC 222nm light is as effective at killing (antibiotic-resistant) bacteria as conventional germicidal UV lamps that use 254nm light, but without any associated skin damage risks.

Download PDF »

Kobe University – May 2020

A Kobe University study published in May 2020 found that far-UVC lamps can be used as an alternative to 254nm, since 222nm exerts a comparable disinfection ability but can be safely used for sterilizing human skin.

Download PDF »

Columbia University Irving Medical Center – June 2020

A Columbia University Irving Medical Center study published in June 2020 found that 99.9% of aerosolized seasonal coronaviruses (that cause the common cold) were inactivated when exposed to far-UVC 222nm light for 25 minutes.

Download PDF »

Kobe University – August 2020

A Kobe University study published in August 2020 suggests that filtered far-UVC light emitted by Care222 lamps can be used to reduce pathogens while people are present.

Download PDF »

Hiroshima University – September 2020

A Hiroshima University study published in September 2020 found that far-UVC 222nm light effectively reduced more than 99.7% of surface contamination of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.

Download PDF »

Ontario Tech University – November 2020

A study published in November 2020 by researchers from Ontario Tech University, Queen Mary University of London, and Cranfield University suggests that disinfection rates with a typical ventilated room are reduced by up to 85% when using far-UVC compared to the room’s ventilation alone, which is particularly significant in poorly ventilated spaces where other means of reduction aren’t practical.

Download PDF »

Resources

Christie CounterAct products with patented Care222 technology are not for use as or for medical devices or for use on humans or animals or to disinfect medical devices

This product is not intended to diagnose, treat, cure, or prevent any disease

The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with American Conference of Governmental Industrial Hygienists (ACGIH) guidelines

All references to “disinfect”, “disinfecting” and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority including the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency. Christie CounterAct products with patented Care222 technology are not medical devices and not to be used with or for medical devices. The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with American Conference of Governmental Institutional Hygienist (ACGIH) guidelines.

The Care222® standard character mark and stylized logo mark are registered trademarks of Ushio America, Inc.’s patented technology, in the United States, European Union, and United Kingdom